Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Soaring Today

By Keith Speights - Mar 12, 2021 at 10:32AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech announced great results for its COVID-19 vaccine.

What happened

Shares of Novavax (NVAX 17.46%) were up 8.1% as of 10:22 a.m. EST on Friday after rising as much as 15.8% earlier in the session. The big gain came after the company announced impressive results from the final analysis of a late-stage study evaluating COVID-19 vaccine candidate NVX-CoV2373.

So what

Investors clearly think that Novavax's final analysis increases the likelihood that NVX-CoV2373 will win Emergency Use Authorization (EUA) in the U.K. and the U.S. They're probably right.

Scientist holding a syringe and a vaccine vial

Image source: Getty Images.

Novavax reported that NVX-CoV2373 provided 100% protection against severe cases of COVID-19. The biotech confirmed an efficacy of 96.4% against the original strain of the SARS-CoV-2, the coronavirus that causes COVID-19. This level is higher than the efficacy levels originally reported for all three of the other COVID-19 vaccines that have won EUA so far in the U.S.

The company also said that it confirmed efficacy for NVX-CoV2373 against newer coronavirus variants discovered in the U.K. and South Africa. As expected, however, the vaccine didn't provide as much protection against these variants. The late-stage study found 86.3% efficacy against the U.K. variant.

Novavax also conducted a phase 2b study in South Africa. NVX-CoV2373 demonstrated an overall efficacy of 48.6% in this clinical trial, with most of the cases of COVID-19 due to the B.1.351 variant first identified in South Africa. The vaccine's efficacy among HIV-negative participants was 55.4%.

Now what

There are two potential catalysts for the biotech stock in the near term. Novavax expects to file for EUA in the U.K. early in the second quarter of 2021. The company hopes to also submit for EUA in the U.S. soon afterward. Just how quickly that filing will come, though, will depend on whether the U.S. Food and Drug Administration allows Novavax to base its submission on its U.K. study results.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$55.29 (17.46%) $8.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.